A Focus On Emerging Markets For Recruitment In Breast Cancer Study, Reduced Enrollment Timelines

A Phase III trial comparing drug treatments in patients with advanced breast cancer previously treated with or resistant to an anthracycline and who are taxane resistant PRA has significant experience conducting oncology trials within Central and Eastern Europe, including Russia, the Ukraine, Belarus, and the Baltic States. Our recent experience includes 12 Phase II–III oncology trials for which we have recruited more than 1,200 patients.

A mid-size, top 5 European pharmaceutical company was conducting a global Phase III study in 770 patients with advanced breast cancer previously treated with or resistant to airmaximus an anthracycline and who are taxane resistant (Figure 1). The study was to be conducted in more than 20 countries, and the sponsor proactively included emerging markets in the global study plans to avoid the need for a rescue phase later.